CFO Webinar 2020 September

Japan Pharma: SG&A trends and the impact of COVID-19 on Commercial activities

The CFO Program for foreign companies in Japan held CFO Webinar "Japan Pharma: SG&A trends & the impact of COVID 19 on Commercial activities" for Japanese Pharma CFOs / CPOs on September 11th, 2020. It attracted approximately 20 participants and received high evaluation.


Companies in Japan are optimizing costs and accelerating innovation in response to changes in government priorities and policies. According to pre-survey conducted for attendees of the webinar, 71% of respondents expect only a small increase in operating expenses over the next 12 months.

Due to the impact of COVID-19, the digitalization has been accelerated in medical industry in Japan and globally such as Digital Marketing, Online & Hybrid Events and New Ways of Working (remote engagement). On the other hand, there are some key considerations that will enable enduring success while driving digitalization. Additionally, the widespread impact of COVID-19 will accelerate the definition of ‘what good looks like’ across G&A spend categories.

Lastly, the guest speaker, Mr. Jim McCready, President of Adobe Japan presented case studies powering Life Science industry through digital experience both before and with COVID-19.

(PDF, 2.3MB)


Date: 11th September, 2020

Time: 8:00 am - 9:00 am


  1. Welcome remark
    • Pankaj Arjunwadkar / Partner, Deloitte Tohmatsu Consulting LLC,  The CFO Program for foreign companies in Japan 
  2. Our perspective on SG&A Trends and the impact of COVID-19
    • Christian Boettcher / Partner, Deloitte Tohmatsu Consulting LLC
    • Peter Bristow / Manager, Deloitte Tohmatsu Consulting LLC
  3. Powering Life Science through Digital Experience
    • Jim McCready / President, Adobe Japan


Did you find this useful?